SURAKSHA · NSE
Suraksha Diagnostic Limited
₹335.1
+1.87% (+₹6.15)
Prev. close
₹328.95
Volume
1,17,799
Delivery %
63.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Suraksha Diagnostic Limited
Suraksha Diagnostic Limited provides pathological and radiological services through diagnostic centers in India. It offers home collection services; pathology services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, haematology, clinical biochemistry and immunology, immunohistochemistry, fluorescence in-situ hybridization, cytogenetics, flow cytometry, newborn screening, and NGS. The company also provides microarray, QF-PCR, FISH, karyotyping, and NIPT services; X-Ray, MRI scan, CT scan, USG, DEXA scan, Mammography, OPG radiology services; ECG, echocardiogram, stress test and treadmill test, wireless holter monitoring, and PFT cardiology services; EEG, EMG, and NCV neurology services; and upper GI and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy gastroenterology services. In addition, it offers clinic services, including dental, physiotherapy, immunology and rheumatology, ENT, eye, and specialty clinics, as well as fetal care; home doctor visit services; online doctor consultation; and doctor curated lab packages for bone and health, men's and women's health, senior citizens, diabetes care, fever, full-body checkups, and at-home packages. The company was founded in 1992 and is based in Kolkata, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ms. Ritu Mittal
Headquarters
Kolkata
Employees
1,600
Website
surakshanet.comExchange
View on NSE ↗Key stats
Market cap
₹1,755.12 Cr
P/E ratio (TTM)
48.8
Dividend yield
0.15%
EPS (TTM)
₹6.90
Beta (1Y · daily vs NIFTY 50)
0.49
Shares float
1.74 Cr
EPS · quarter ended Jun 2026
₹2.50
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹190.13 Cr | ₹218.71 Cr | ₹252.09 Cr | ₹310.41 Cr | |
| EBITDA | ₹47.48 Cr | ₹72.84 Cr | ₹85.09 Cr | ₹98.56 Cr |
| ₹6.52 Cr | ₹23.63 Cr | ₹30.98 Cr | ₹31.40 Cr | |
| Diluted EPS | ₹1.25 | ₹4.54 | ₹5.97 | ₹6.18 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹281.20 Cr | ₹300.20 Cr | ₹333.52 Cr | ₹448.12 Cr | |
| ₹96.87 Cr | ₹90.48 Cr | ₹88.89 Cr | ₹130.34 Cr | |
| Stockholders' equity | ₹155.93 Cr | ₹179.41 Cr | ₹211.24 Cr | ₹244.85 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹44.10 Cr | ₹60.48 Cr | ₹63.36 Cr | ₹81.83 Cr | |
| Investing cash flow | ₹-20.80 Cr | ₹-35.00 Cr | ₹-39.58 Cr | ₹-52.17 Cr |
| ₹-24.33 Cr | ₹-25.13 Cr | ₹-24.05 Cr | ₹-28.69 Cr | |
| Capital expenditure | ₹-13.17 Cr | ₹-45.47 Cr | ₹-42.02 Cr | ₹-67.34 Cr |
| End cash position | ₹2.16 Cr | ₹2.52 Cr | ₹2.25 Cr | ₹3.21 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 24–Mar 25(3Q) | Jun 25 | Sep 25 | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|
| Promoter | 48.78% | 48.88% | 48.98% | 49.00% | 49.10% |
| Public | 51.22% | 51.12% | 51.02% | 51.00% | 50.90% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Suraksha Diagnostic Limited | ₹1,710.07 Cr | ₹328.95 | 47.7 | 6.98 | 13.1% | 0.53 | +23.1% | +1.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.